| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5508038 | CHATTEM SANOFI | Polyisobutylene adhesives for transdermal devices |
Apr, 2013
(11 years ago) | |
| US9205059 | CHATTEM SANOFI | Transparent transdermal nicotine delivery devices |
Dec, 2019
(4 years ago) | |
| US8999379 | CHATTEM SANOFI | Transparent transdermal nicotine delivery devices |
Feb, 2020
(4 years ago) | |
| US8663680 | CHATTEM SANOFI | Transparent transdermal nicotine delivery devices |
Feb, 2020
(4 years ago) | |
| US8075911 | CHATTEM SANOFI | Transparent transdermal nicotine delivery devices |
May, 2021
(2 years ago) | |
Nicoderm Cq is owned by Chattem Sanofi.
Nicoderm Cq contains Nicotine.
Nicoderm Cq has a total of 5 drug patents out of which 5 drug patents have expired.
Expired drug patents of Nicoderm Cq are:
- US5508038
- US9205059
- US8999379
- US8663680
- US8075911
Nicoderm Cq was authorised for market use on 02 August, 1996.
Nicoderm Cq is available in film, extended release;transdermal dosage forms.
Nicoderm Cq can be used as a method to reduce withdrawal symptoms, including nicotine craving, associated with smoking cessation.
The generics of Nicoderm Cq are possible to be released after 22 May, 2021.
Drugs and Companies using NICOTINE ingredient
Market Authorisation Date: 02 August, 1996
Treatment: A method to reduce withdrawal symptoms, including nicotine craving, associated with smoking cessation
Dosage: FILM, EXTENDED RELEASE;TRANSDERMAL
NICODERM CQ family patents
